Vanguard Capital Management
CBIO

Vanguard Capital Management’s Crescent Biopharma CBIO Stock Holding History

Vanguard Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.8M Sell
767,755
-33,640
-4% -$657K ﹤0.01% 2638
2026
Q1 		$14.7M Buy
+801,395
New +$9.2M ﹤0.01% 2512

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management's CBIO Position: Q2 2026 in Review

Vanguard Capital Management reduced its Crescent Biopharma (CBIO) stake by 4.2% in Q2 2026, selling an estimated $657K and leaving 767,755 shares worth $13.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2638.

Vanguard Capital Management first reported a position in CBIO in Q1 2026 and has held it in 2 quarters since. The position peaked at $14.7M in Q1 2026. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Vanguard Capital Management held 767,755 shares of Crescent Biopharma worth $13.8M as of Q2 2026.
  • Vanguard Capital Management sold 33,640 Crescent Biopharma shares in Q2 2026, an estimated $657K.
  • Crescent Biopharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2638 holding.
  • Vanguard Capital Management first reported a position in Crescent Biopharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Crescent Biopharma position peaked at $14.7M in Q1 2026.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.